Detalhe da pesquisa
1.
Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
Ann Oncol
; 33(6): 668, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35487836
2.
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Ann Oncol
; 28(10): 2340-2366, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945867
3.
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
Ann Oncol
; 32(9): 1077-1082, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34082017
4.
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol
; 26(8): 1547-73, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26026162
5.
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Ann Oncol
; 25(8): 1544-50, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24608200
6.
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.
Ann Oncol
; 29(3): 774-775, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161364
7.
Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.
Ann Oncol
; 29(2): 521-522, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045537
8.
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol
; 28(11): 2901-2905, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27604385
9.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Ann Oncol
; 28(12): 3111, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327998
10.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Ann Oncol
; 28(1): 16-33, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177437
11.
Long-term toxic effects of adjuvant chemotherapy in breast cancer.
Ann Oncol
; 22(9): 1939-1947, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21289366
12.
Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.
Ann Oncol
; 27(1): 205-207, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32645815
13.
Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.
Ann Oncol
; 27(11): 2136-2137, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573563
14.
Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.
Ann Oncol
; 27(1): 203-5, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26519490
15.
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
Ann Oncol
; 25(10): 1871-1888, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234545
16.
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Br J Cancer
; 98(9): 1500-7, 2008 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-18454159
17.
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Ann Oncol
; 19(5): 877-82, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18332043
18.
Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.
Ann Oncol
; 23 Suppl 6: vi5-6, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23012303
19.
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Eur J Cancer
; 79: 98-105, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28477490
20.
Long-term survival in pituitary metastasis from breast cancer.
Breast
; 15(3): 446-7, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16081288